White House sources indicate Trump approved Makary’s removal, reflecting escalating senior leadership churn across federal health agencies. Makary’s tenure featured MAHA-aligned regulatory positions, ...

In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst ...

In today’s Pharmaceutical Executive Daily, the FDA extends its priority review of a subcutaneous formulation of Leqembi, industry analysts examine how upcoming GLP-1 patent expirations could reshape ...

Consideration is set at $31.50 per Catalyst share in cash, implying an equity value above $4.1 billion and a 21% premium to ...

Madrigal Pharmaceuticals entered an exclusive global license agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a ...

Pharmaceutical Executive: What elements is the conversation about bringing pharma manufacturing home missing? Charlie Lyon: ...

In March of this year, the API Innovation Center released its whitepaper titled, “From Fragility to Resilience: Aligning ...

Natalie de Graaf is VP and GM of Data, AI and ML; Solutions for Health and National Security at the API Innovation Center. Natalie de Graaf, from the API Innovation Center, discusses a recent ...

Pharmaceutical Executive spoke with Aradigm Health CEO Will Shrank at the Asembia ASX26 Summit in Las Vegas. During the conversation, he explained the issues the payers face with cell & gene therapies ...

In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for ...

Ultimately, making RWE actionable means shortening the gap between insight and application. When data is reliable, complete, and easy to use, it can support better decisions, faster adoption of new ...

ASPENOVA randomizes Cyclin E1-positive PROC to azenosertib versus paclitaxel, PLD, gemcitabine, or topotecan, reflecting current NCCN sequential single-agent practice. PFS is the primary endpoint, ...